Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib vs Sunitinib in Imatinib-Resistant GIST
NCT01694277Phase 3Completed
- Sponsor
- AB Science
- Start
- Apr 2012
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of masitinib in gastrointestinal stromal tumor (GIST) (2 arms), sponsored by AB Science. Primary endpoint: Overall Survival at 60 months. Started Apr 2012; status: completed.
02
Drugs
masitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT01694277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01694277.